TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · see citing works

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,181 · see citing works

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works

MYC regulates the antitumor immune response through CD47 and PD-L1

Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403 · see citing works

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 830 · see citing works

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796 · see citing works

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776 · see citing works

Programmed death ligand-1 expression in non-small cell lung cancer

Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 752 · see citing works

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688 · see citing works

PDL1 Regulation by p53 via miR-34

Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683 · see citing works

Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G. T., Béné, M. C., Vos, J. D., Hernández‐Rivas, J. M., Hofmann, W., Mills, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4732 · Cited by 657 · see citing works

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595 · see citing works

A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies

Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441 · see citing works

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation

Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396 · see citing works

miR-34 miRNAs provide a barrier for somatic cell reprogramming

Choi, Y. J., Lin, C., Ho, J. J., He, X., Okada, N., Bu, P., Zhong, Y., Kim, S. Y., Bennett, M. J., Chen, C., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2366 · Cited by 381 · see citing works

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation

Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 351 · see citing works

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330 · see citing works

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

Wang, X., Li, J., Dong, K., Fang, L., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313 · see citing works

Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia

Szczepański, M. J., Szajnik, M. E., Czystowska, M., Mandapathil, M., Strauss, L., Welsh, A., Foon, K. A., Whiteside, T. L., & Boyiadzis, M. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3010 · Cited by 304 · see citing works

The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy

Buchan, S. L., Rogel, A., & Al‐Shamkhani, A. (2017) · Blood · doi:10.1182/blood-2017-07-741025 · Cited by 276 · see citing works

A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.

Kikushige, Y., Miyamoto, T., Yuda, J., Jabbarzadeh-Tabrizi, S., Shima, T., Takayanagi, S.-I., Niiro, H., Yurino, A., Miyawaki, K., Takenaka, K., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.07.011 · Cited by 262 · see citing works

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation

Porta, M. G. D., Gallì, A., Bacigalupo, A. P., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., Lint, M. T. V., Pioltelli, P. E., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 255 · see citing works

PD-1 marks dysfunctional regulatory T cells in malignant gliomas

Lowther, D. E., Goods, B. A., Lucca, L. E., Lerner, B., Raddassi, K., van Dijk, D., Hernandez, A. L., Duan, X.-G., Gunel, M., Coric, V., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85935 · Cited by 237 · see citing works

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231 · see citing works

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Wang, Y., Wang, H., Yao, H., Li, C., Fang, J., & Xu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00536 · Cited by 209 · see citing works

Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes

Kondo, A., Yamashita, T., Tamura, H., Zhao, W., Tsuji, T., Shimizu, M., Shinya, E., Takahashi, H., Tamada, K., Chen, L., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255125 · Cited by 201 · see citing works

Activation of c- myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain

Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194 · see citing works

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

Zhang, B., Chikuma, S., Hori, S., Fagarasan, S., & Honjo, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608873113 · Cited by 166 · see citing works

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Vadakekolathu, J. N., Lai, C., Reeder, S., Church, S., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I. T., Advani, A. S., Godwin, J. E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002512 · Cited by 156 · see citing works

MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells

Yamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Deng, G., & Dahiya, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029722 · Cited by 152 · see citing works

Increased population of CD4 + CD25 high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients

Wang, X., Zheng, J., Liu, J., Yao, J., He, Y., Li, X., Yu, J., Yang, J. X., Liu, Z., & Huang, S. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00537.x · Cited by 147 · see citing works

Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival

Tu, J., Ding, Y., Ying, X., Wu, F., Zhou, X.-M., Zhang, D.-K., Zou, H., & Ji, J. (2016) · Scientific Reports · doi:10.1038/srep35056 · Cited by 144 · see citing works

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A. G., Göhring, G., Giagounidis, A. A. N., Selleslag, D., Muus, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098103 · Cited by 137 · see citing works

Clinical significance of B7-H1（PD-L1）expression in human acute leukemia

Chen, X., Liu, S., Wang, L., Zhang, W., Ji, Y., & Ma, X. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5689 · Cited by 122 · see citing works

S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes

Cheng, P., Eksioglu, E. A., Chen, X., Kandell, W. M., Trinh, T. L., Cen, L., Qi, J., Sallman, D. A., Zhang, Y., Tu, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0397-9 · Cited by 103 · see citing works

Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy

Amatore, F., Gorvel, L., & Olive, D. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1444753 · Cited by 95 · see citing works

MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma

Yamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Chang, I., Tanaka, Y., Gupta, A. K., & Dahiya, R. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr286 · Cited by 90 · see citing works

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

Albring, J. C., Inselmann, S., Sauer, T., Schliemann, C., Altvater, B., Kailayangiri, S., Rössig, C., Hartmann, W., Knorrenschild, J. R., Sohlbach, K., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.274 · Cited by 84 · see citing works

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Garcia‐Manero, G., Sasaki, K., Bravo, G. M., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119424 · Cited by 68 · see citing works

Decitabine inTP53-Mutated AML

Welch, J. S., Petti, A. A., & Ley, T. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616062 · Cited by 56 · see citing works

Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer

Mo, L., Chen, Q., Zhang, X., Shi, X., Wei, L., Zheng, D., Li, H., Gao, J., Li, J., & Hu, Z. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.08.093 · Cited by 50 · see citing works

Expression of CD 274 ( PD ‐L1) is associated with unfavourable recurrent mutations in AML

Zajac, M., Zaleska, J., Dolnik, A., Bullinger, L., & Giannopoulos, K. (2017) · British Journal of Haematology · doi:10.1111/bjh.15040 · Cited by 20 · see citing works

Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

Garcia‐Manero, G., Bravo, G. M., Sasaki, K., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118948 · Cited by 14 · see citing works

Abstract LB-222: Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease

Daver, N. G., Kantarjian, H. M., Mackay, S., Flynn, B., Basu, S., Garcia‐Manero, G., Alfayez, M., Konopleva, M. Y., Matthews, J. A., Kornblau, S. M., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-lb-222 · Cited by 6 · see citing works

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemiaPreprint

Lai, C., Vadakekolathu, J. N., Reeder, S., Church, S., Hood, T., Aldoss, I. T., Godwin, J. E., Wieduwilt, M. J., Arellano, M. L., MUTH, J. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.28.961391 · Cited by 3 · see citing works

MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic

Li, W., Wang, Y., Liu, R., Kasinski, A. L., Shen, H., Slack, F. J., & Tang, D. G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.640587 · Cited by 195 · see citing works

TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

Sallman, D. A., Kerre, T. C. C., Havelange, V., Poiré, X., Lewalle, P., Wang, E. S., Brayer, J. B., Davila, M. L., Moors, I., Machiels, J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00378-7 · Cited by 102 · see citing works

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia

Rutella, S., Vadakekolathu, J. N., Mazziotta, F., Reeder, S., Yau, T. O., Mukhopadhyay, R., Dickins, B., Altmann, H., Krämer, M., Knaus, H. A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159579 · Cited by 96 · see citing works

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 98 · see citing works

The role of p53 in anti-tumor immunity and response to immunotherapy

Carlsen, L., Zhang, S., Tian, X., Cruz, A. D. L., George, A., Arnoff, T. E., & El‐Deiry, W. S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1148389 · Cited by 92 · see citing works

Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

Versluis, J., Saber, W., Tsai, H. K., Gibson, C. J., Dillon, L. W., Mishra, A., McGuirk, J., Maziarz, R. T., Westervelt, P., Hegde, P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00866 · Cited by 78 · see citing works

Escape from T-cell–targeting immunotherapies in acute myeloid leukemia

Vadakekolathu, J. N., & Rutella, S. (2023) · Blood · doi:10.1182/blood.2023019961 · Cited by 73 · see citing works

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Abaza, Y., & Zeidan, A. M. (2022) · Cells · doi:10.3390/cells11142249 · Cited by 73 · see citing works

Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells

Corradi, G., Bassani, B., Simonetti, G., Sangaletti, S., Vadakekolathu, J. N., Fontana, M. C., Pazzaglia, M., Gulino, A., Tripodo, C., Cristiano, G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3594 · Cited by 70 · see citing works

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

Chien, K. S., Kim, K., Nogueras‐González, G. M., Borthakur, G. M., Naqvi, K., Daver, N. G., Bravo, G. M., Cortes, J. E., Dinardo, C. D., Jabbour, E. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17689 · Cited by 62 · see citing works

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Fiorenza, S., & Turtle, C. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00477-8 · Cited by 57 · see citing works

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?

Allen, C., Zeidan, A. M., & Bewersdorf, J. P. (2021) · Life · doi:10.3390/life11060465 · Cited by 57 · see citing works

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Loke, J. C. T., Labopin, M., Craddock, C., Cornelissen, J. J., Labussière‐Wallet, H., Wagner-Drouet, E., van Gorkom, G. N. Y., Schaap, N. P., Kröger, N. M., Veelken, J. H., et al. (2022) · Cancer · doi:10.1002/cncr.34268 · Cited by 54 · see citing works

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinicPreprint

Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 52 · see citing works

Targeting the innate immune system in pediatric and adult AML

Perzolli, A., Koedijk, J. B., Zwaan, C. M., & Heidenreich, O. T. (2024) · Leukemia · doi:10.1038/s41375-024-02217-7 · Cited by 51 · see citing works

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Voso, M. T., Falconi, G., & Fabiani, E. (2021) · Blood · doi:10.1182/blood.2021010764 · Cited by 55 · see citing works

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 50 · see citing works

Inflammation and myeloid malignancy: quenching the flame

Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 46 · see citing works

CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells

Wen, Y., Xia, Y., Yang, X., Li, H., & Gao, Q. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.01.001 · Cited by 44 · see citing works

TP53 in MDS and AML: Biological and clinical advances

Zhao, Y., Chen, W., Yu, J., Pei, S., Zhang, Q., Shi, J., Huang, H., & Zhao, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216767 · Cited by 44 · see citing works

TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates

Santini, V., Stahl, M. F., & Sallman, D. A. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432650 · Cited by 43 · see citing works

TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

Shah, M. V., Arber, D. A., & Hiwase, D. (2025) · American Journal of Hematology · doi:10.1002/ajh.27655 · Cited by 41 · see citing works

Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax

Chen, E. C., Liu, Y., Harris, C. E., Winer, E. S., Wadleigh, M., Lane, A. A., Vedula, R. S., Lindsley, R. C., Copson, K. M., Charles, A. L., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2047964 · Cited by 36 · see citing works

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia

Mohty, R., Hamed, R. A., Brissot, É., Bazarbachi, A. A., & Mohty, M. (2023) · Haematologica · doi:10.3324/haematol.2022.280798 · Cited by 36 · see citing works

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells

Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33 · see citing works

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Gallazzi, M., Ucciero, M. A. M., Faraci, D., Mahmoud, A. M., Essa, W. A., Gaïdano, G., Mouhssine, S., & Crisà, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147542 · Cited by 32 · see citing works

TP53-mutated acute myeloid leukemia: how can we improve outcomes?

Sallman, D. A., & Stahl, M. F. (2024) · Blood · doi:10.1182/blood.2024024245 · Cited by 31 · see citing works

TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress

Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 30 · see citing works

Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease

Mannelli, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030436 · Cited by 30 · see citing works

Transplant for TP53-mutated MDS and AML: because we can or because we should?

Versluis, J., & Lindsley, R. C. (2022) · Hematology · doi:10.1182/hematology.2022000354 · Cited by 30 · see citing works

p53 mutation and deletion contribute to tumor immune evasion

Liu, S. M., Liu, T., Jiang, J., Guo, H., & Yang, R. L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1088455 · Cited by 28 · see citing works

Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia

Zhang, Z., Huang, J., Zhang, Z., Shen, H., Tang, X., Wu, D., Bao, X., Xu, G., & Chen, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00600-1 · Cited by 30 · see citing works

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia

Ragaini, S., Wagner, S., Marconi, G., Parisi, S., Sartor, C., Nanni, J., Cristiano, G., Talami, A., Olivi, M., Očadlíková, D., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004878 · Cited by 28 · see citing works

Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment

Serroukh, Y. I. M., Hébert, J., Busque, L., Mercier, F., Rudd, C. E., Assouline, S. E., Lachance, S., & Delisle, J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100991 · Cited by 27 · see citing works

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Mascarenhas, J. O., Passamonti, F., Burbury, K., El‐Galaly, T. C., Gerds, A. T., Gupta, V. K., Higgins, B., Wonde, K., Jamois, C., Kovic, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006043 · Cited by 26 · see citing works

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Gagelmann, N., Badbaran, A., Salit, R. B., Schroeder, T. A., Gurnari, C., Pagliuca, S., Panagiota, V., Rautenberg, C., Cassinat, B., Thol, F. R., et al. (2023) · Blood · doi:10.1182/blood.2023019630 · Cited by 27 · see citing works

The promise of macrophage directed checkpoint inhibitors in myeloid malignancies

Swoboda, D. M., & Sallman, D. A. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101221 · Cited by 25 · see citing works

Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes

Shimony, S. O., Stone, R. M., & Stahl, M. F. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000698 · Cited by 24 · see citing works

Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review

Lynch, O. F., & Calvi, L. M. (2022) · Cells · doi:10.3390/cells11030580 · Cited by 26 · see citing works

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis

Herrera, D. A., Sparks, A. D., Singh, R., Alejos, D., Batra, A., Glushakow-Smith, S. G., Pradhan, K., Shastri, A., & Zakai, N. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011050 · Cited by 22 · see citing works

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Barakos, G. P., & Hatzimichael, E. C. (2022) · Diseases · doi:10.3390/diseases10020033 · Cited by 22 · see citing works

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges

Chen, Y., Wang, J., Zhang, F., & Liu, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1151032 · Cited by 22 · see citing works

Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma

Fan, T. T., Liu, Y., Liu, H., Wang, L., Tian, H., Zheng, Y., Zheng, B. J., Xue, L., Li, C., & He, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.828814 · Cited by 21 · see citing works

Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors

Ikeda, D., Chi, S., Uchiyama, S., Nakamura, H., Guo, Y., Yamauchi, N., Yuda, J., & Minami, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115950 · Cited by 21 · see citing works

Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies

Bruserud, Ø., Selheim, F., Hernandez-Valladares, M., & Reikvam, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126356 · Cited by 21 · see citing works

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 20 · see citing works

Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies

Zha, C., Yang, X., Yang, J., Zhang, Y., & Huang, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06117-9 · Cited by 22 · see citing works

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

Zampini, M., Riva, E., Lanino, L., Sauta, E., Reis, R. A. D., Ejarque, R. A., Maggioni, G., Termanini, A., Merlotti, A., Campagna, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02394 · Cited by 21 · see citing works

TP53 in Myelodysplastic Syndromes

Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 21 · see citing works

CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia

Kaito, Y., Hirano, M., Futami, M., Nojima, M., Tamura, H., Tojo, A., & Imai, Y. (2021) · Oncology Letters · doi:10.3892/ol.2021.13169 · Cited by 20 · see citing works

Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS

Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 20 · see citing works

Ferroptosis-related molecular patterns reveal immune escape, inflammatory development and lipid metabolism characteristics of the tumor microenvironment in acute myeloid leukemia

Zhong, F., Yao, F., Liu, J., Zhang, H., Zhang, J., Zhang, N., Jin, L., Li, S., Li, M., Jiang, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888570 · Cited by 20 · see citing works

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 20 · see citing works

From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression

Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., & Voso, M. T. (2021) · Biology · doi:10.3390/biology10020128 · Cited by 21 · see citing works

Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease

Veiga, C. B., Lawrence, E., Murphy, A. J., Herold, M. J., & Dragoljevic, D. (2021) · Cancers · doi:10.3390/cancers13081968 · Cited by 19 · see citing works

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 19 · see citing works

Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship

Granata, V., Crisafulli, L., Nastasi, C., Ficara, F., & Sobacchi, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884024 · Cited by 19 · see citing works

Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications

Hart, S. A., Lee, L. A., Seegmiller, A. C., & Mason, E. F. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014140 · Cited by 19 · see citing works

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments

Pagliuca, S., Gurnari, C., & Visconte, V. (2021) · Cancers · doi:10.3390/cancers13040784 · Cited by 18 · see citing works

Progress toward Better Treatment of Therapy-Related AML

Kotsiafti, A., Giannakas, K., Christoforou, P., & Liapis, K. (2023) · Cancers · doi:10.3390/cancers15061658 · Cited by 17 · see citing works

Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia

Wang, P., Zhang, Y., Cai, Q., Long, Q., Pan, S., Zhou, W., Deng, T., Mo, W., Wang, S., Zhang, Y., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2201507 · Cited by 17 · see citing works

Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression

Jambhekar, A., Ackerman, E. E., Alpay, B. A., Lahav, G., & Lovitch, S. B. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100004 · Cited by 17 · see citing works

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Assouline, S. E., Michaelis, L. C., Othus, M. K. D., Hay, A. E., Walter, R. B., Jacoby, M. A., Schroeder, M. A., Uy, G. L., Law, L. Y., Cheema, F. E., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2148212 · Cited by 15 · see citing works

Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia

Luo, D., Liu, S., Luo, J., Chen, H., He, Z., Gao, Z., Wen, Z., Liu, X., & Xu, N. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03118-4 · Cited by 15 · see citing works

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

Kuszczak, B., Wróbel, T., Wicherska‐Pawłowska, K., & Rybka, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054708 · Cited by 15 · see citing works

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia

Patel, S. A. (2024) · Leukemia · doi:10.1038/s41375-024-02417-1 · Cited by 15 · see citing works

Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine

Zeidan, A. M., Bewersdorf, J. P., Hasle, V., Shallis, R. M., Thompson, E. G., Menezes, D. L. D., Rose, S., Boss, I. W., Halene, S., Haferlach, T., et al. (2024) · Therapeutic Advances in Hematology · doi:10.1177/20406207241257904 · Cited by 15 · see citing works

Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)

Kállai, A., Ungvari, A., Csabán, D., Őrfi, Z., Lehoczki, A., Harasztdombi, J., Yabluchanskiy, A., Benyó, Z., Szappanos, Á., Tarantini, S., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01654-1 · Cited by 14 · see citing works

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape

Schwind, S., Jentzsch, M., Kubasch, A. S., Metzeler, K. H., & Platzbecker, U. (2021) · Neoplasia · doi:10.1016/j.neo.2021.09.002 · Cited by 14 · see citing works

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease

Mohty, R., Hamed, R. A., Bazarbachi, A. A., Brissot, É., Nagler, A., Zeidan, A. M., & Mohty, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01346-9 · Cited by 14 · see citing works

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

Loschi, M. L., Fenaux, P., & Cluzeau, T. (2022) · Cancers · doi:10.3390/cancers14184519 · Cited by 15 · see citing works

Therapy-related myelodysplastic syndromes in the genomics era

Renneville, A., Bernard, E., & Micol, J. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.02.022 · Cited by 14 · see citing works

Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia

Matthews, A. H., Pratz, K., & Carroll, M. (2022) · Cancers · doi:10.3390/cancers14235906 · Cited by 11 · see citing works

Myeloid-derived suppressor cells: a grey eminence in the AML tumor microenvironment?

Bewersdorf, J. P., & Zeidan, A. M. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2030227 · Cited by 13 · see citing works

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes

Xu, T., Yang, T., Yuan, B., Yang, Y., Liu, J., Wang, X., Wang, Y., Ma, T., Yin, X. H., Yu, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177133 · Cited by 12 · see citing works

Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target

Quattrocchi, A., Cappelli, L. V., Simone, G. D., Marinis, E. D., Gentile, M., Gasperi, T., Pulsoni, A., Ascenzi, P., & Nervi, C. (2023) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2023.100023 · Cited by 12 · see citing works

TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Marvin‐Peek, J., Mason, E. F., Kishtagari, A., Jayani, R., Dholaria, B., Kim, T. K., Engelhardt, B. G., Chen, H., Strickland, S. A., Savani, B. N., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.008 · Cited by 12 · see citing works

Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma

Ma, B., Jiang, H., Luo, Y., Liao, T., Xu, W., Wang, X., Dong, C., Ji, Q., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692079 · Cited by 12 · see citing works

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics

Santoro, N., Salutari, P., Ianni, M. D., & Marra, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084259 · Cited by 10 · see citing works

New Treatment Options for Older Patients with Acute Myeloid Leukemia

Saxena, K., & Konopleva, M. Y. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00841-4 · Cited by 11 · see citing works

TP53 -mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology

Patel, S. A., & Černý, J. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006580 · Cited by 11 · see citing works

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

Bauer, M., Vaxevanis, C., Al‐Ali, H. K., Jaekel, N., Naumann, C. L. H., Schaffrath, J., Rau, A., Seliger, B., & Wickenhauser, C. (2021) · Cancers · doi:10.3390/cancers13020186 · Cited by 10 · see citing works

Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes

Meunier, M., Laurin, D., & Park, S. (2023) · Cells · doi:10.3390/cells12040658 · Cited by 10 · see citing works

A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors

Lu, Y., Li, D., Cao, Y., Ying, L., Qing, T., Xiong, F., Hu, Z., Yang, Y., Qiao, X., Chen, P., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.862294 · Cited by 10 · see citing works

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?

Shallis, R. M., Bewersdorf, J. P., Stahl, M. F., Halene, S., & Zeidan, A. M. (2022) · Cancers · doi:10.3390/cancers14102434 · Cited by 11 · see citing works

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

Comont, T., Treiner, E., & Vergez, F. (2021) · Diagnostics · doi:10.3390/diagnostics11111982 · Cited by 10 · see citing works

Immunity in acute myeloid leukemia: Where the immune response and targeted therapy meet

Fink, A., Hung, E., Singh, I., & Ben‐Neriah, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202048945 · Cited by 9 · see citing works

Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications

Simoni, Y., & Chapuis, N. (2022) · Diagnostics · doi:10.3390/diagnostics12071659 · Cited by 9 · see citing works

Gut Microbiota in Acute Myeloid Leukemia: From Biomarkers to Interventions

Ji, M., Ji, M., Zhong, Y., & Shao, L. (2025) · Metabolites · doi:10.3390/metabo15090568 · Cited by 9 · see citing works

Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels

Lin, X., Gu, Y. J., Su, Y., Dong, Y., Major, P. P., Kapoor, A., & Tang, D. (2022) · Cancers · doi:10.3390/cancers14112805 · Cited by 9 · see citing works

Immunophenotyping myelodysplastic neoplasms: the role of flow cytometry in the molecular classification era

Verigou, E., Chatzilygeroudi, T., Lazaris, V., de Lastic, A.-L., & Symeonidis, A. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447001 · Cited by 8 · see citing works

Biology of post-transplant relapse: actionable features

Orofino, G., & Vago, L. (2024) · Hematology · doi:10.1182/hematology.2024000588 · Cited by 8 · see citing works

TP53 ‐Mutated Acute Myeloid Leukemia: Unanswered Questions

Bruzzese, A., Vigna, E., Martino, E. A., Labanca, C., Caridà, G., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70106 · Cited by 10 · see citing works

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant

Zanwar, S., Jacob, E. K., Greiner, C. W., Pavelko, K. D., Strausbauch, M. A., Anderson, E., Arsana, A., Weivoda, M. M., Shah, M. V., & Kourelis, T. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00920-9 · Cited by 8 · see citing works

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment

Zhang, P., Whipp, E. C., Skuli, S. J., Gharghabi, M., Saygin, C., Sher, S., Carroll, M. P., Pan, X., Eisenmann, E. D., Lai, T.-H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184021 · Cited by 8 · see citing works

Bone marrow tumor microenvironment profiling predicts distinct immunosuppressive phenotypes and immunotherapy potential in AML patients.

da Cruz, L. C., Lee, Y.-J., Paik, J. Y., Park, J., Diederich, M., & Cerella, C. (2025) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2025.118287 · Cited by 9 · see citing works

Molecular and Clinical Insights into TP53-Mutated MDS and AML

Georgantzinos, E., & Karantanos, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210818 · Cited by 7 · see citing works

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML ‐001 trial

Menezes, D. L. D., See, W. L., Risueño, A., Tsai, K.-T., Lee, J. K., Ma, J., Khan, R., Prébet, T., Skikne, B., Beach, C. L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18783 · Cited by 7 · see citing works

OMIP‐106: A 30‐color panel for analysis of check‐point inhibitory networks in the bone marrow of acute myeloid leukemia patients

Musil, J., Ptacek, A., & Vaníková, Š. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24892 · Cited by 7 · see citing works

Natural born survivors: the inglorious TP53

Platzbecker, U., & Kordasti, S. Y. (2020) · Blood · doi:10.1182/blood.2020008212 · Cited by 4 · see citing works

Marrow Microenvironmental Pathobiology and Therapeutic Opportunities for TP53-Mutated Myelodysplastic Syndrome/Acute Myeloid Leukemia

Hunter, C. J., Im, A., & Shallis, R. M. (2026) · Cancers · doi:10.3390/cancers18020275 · Cited by 4 · see citing works

Immunosuppressive T-cell landscape in myelodysplastic Neoplasms with TP53 mutations

Jiang, L., Ye, L., Huang, X., Zhou, X., Wang, W., Wang, L., Zhang, Y., Sun, J., & Tong, H. (2025) · Blood · doi:10.1182/blood-2025-3833

TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies

Albakri, M. M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1655486 · Cited by 12 · see citing works